• Introduction
• 16 min
  1. Psychopharmacology: structural aspects of the brain

  • Prof. Brian Leonard
• 66 min
  2. The nature of chemical neurotransmission

  • Prof. Brian Leonard
• 28 min
  3. Psychotropic drugs

  • Prof. Brian Leonard
• 26 min
  4. Psychopharmacology of anxiety disorders

  • Prof. Brian Leonard
• 35 min
  5. Psychopharmacology of depression

  • Prof. Brian Leonard
• 48 min
  6. Psychopharmacology of mania and schizophrenia

  • Prof. Brian Leonard
• 45 min
  7. The role of stress and immune system in psychiatric disorders

  • Prof. Brian Leonard
• Introduction to Genetic Investigations of Complex Traits
• 39 min
  8. Genetic association studies, TDT and the candidate gene approach

  • Dr. Jo Knight
• Genetics and Pharmacokinetics of Psychotropic Drugs
• 34 min
  9. Genetics of phase I enzymes

  • Prof. Aiming Yu
• 36 min
  10. Phase II metabolism

  • Prof. Ann Daly
• Genetics and Pharmacodynamics of Psychotropic Drugs
• 25 min
  11. Genetics and psychotropic drugs: present and future clinical applications

  • Dr. Chiara Fabbri
• 25 min
  12. Influence of neurotransmitter receptor variants on interactions with psychotropic drugs

  • Dr. Maria Arranz
• 51 min
  13. Pharmacogenetics of antidepressants

  • Prof. Alessandro Serretti
• Clinical Applications of Psychopharmacogenetics
• 41 min
  14. Of genes and drugs: genetic determinants of adverse drug reactions

  • Dr. Mario Masellis
• 35 min
  15. Cocaine and amphetamine addiction genetics

  • Dr. Gerome Breen
• 29 min
  16. Tailoring psychiatric treatment using genetic information: pharmacogenetic prediction of treatment response

  • Dr. Maria Arranz
• Archived Lectures *These may not cover the latest advances in the field
• 47 min
  17. Genetic, environmental and other design issues relevant for pharmacogenetics studies

  • Dr. Ridha Joober
• 37 min
  18. Genetic determinants of metabolism: clinical applications in psychiatry

  • Prof. Julia Stingl (formerly Kirchheiner)
• 36 min
  19. Rapid methods for the genetic determination of pharmacokinetic status

  • Dr. Paul Debenham
• 47 min
  20. Genetic polymorphisms influencing response to lithium

  • Prof. Alessandro Serretti
• 28 min
  21. Genetic determinants of antipsychotic-induced weight gain

  • Prof. Gavin Reynolds
• 59 min
  22. Pharmacogenetics of tardive dyskinesia: a "movement" towards individualized therapy 1

  • Dr. Vincenzo Basile
• 50 min
  23. Pharmacogenetics of tardive dyskinesia: a "movement" towards individualized therapy 2

  • Dr. Vincenzo Basile
• 37 min
  24. Genetic determinants of agranulocytosis

  • Dr. Michael Dettling
• 52 min
  25. Genetic polymorphisms influencing the response of antidepressants

  • Prof. Alessandro Serretti

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Objectives
3. How do you define ADR?
4. How common are ADRs?
5. What are the costs of ADRs?
6. Benefit-to-risk profile
7. Classification of ADRs (1)
8. Classification of ADRs (2)
9. Pharmacokinetics and pharmacodynamics
10. PK-PD Paradigm
11. Route of oral medication
12. Pharmacology
13. Example of a type A ADR (1)
14. Schizophrenia
15. Dopamine hypothesis
16. Correllation between dose-effect
17. CNS dopamine pathway
18. Dopamine receptors neuroanatomical distributions
19. Example of a type A ADR
20. Example of a type B ADR
21. Mechanism of drug induced toxicity
22. Carbamazepine-induced erythema multiforme
23. Variability in drug response
24. Summary
25. Goal of pharmacogenetics
26. Pharmacogenetics
27. Genotype, phenotype - definitions
28. How genotype and phenotype related to each other
29. Gene, polymorphism, allele - definitions
30. PK-PD paradigm in pharmacogenetics
31. Route of psychotrophic drugs
32. Polygenic drug response
33. Comic relief
34. Demographic and environmental factors in ADRs
35. Examples of G-E interactions
36. Functional polymorphisms in CYP1A2
37. PGX methods applied to ADRs
38. Central hypotheses
39. Genetic association strategy
40. Alternative genetic association strategy
41. Candidate gene polymorphisms
42. Selected examples
43. Example of PK polymorphism and ADR
44. PGX as applied to debrisoquine
45. PGX as applied to succinylcholine
46. Example of PD polymorphism and ADR
47. PGX as applied to beta-adrenergic agonists
48. PGX as applied to quetiapine
49. Long QT syndrome mechanism
50. Limitations to current strategies
51. What are endophenotypes?
52. Genotype-endophenotype-phenotype
53. Endophenotype of D1 receptor alleles
54. Endophenotype of DRD1 Ddel polymorphism
55. Other examples and references
56. Phase 1 CYP450 polymorphisms and ADRs
57. PD polymorphisms and ADRs
58. Phase 2 enzyme polymorphisms and ADRs
59. Target and transporter polymorphisms and ADRs
60. HLA immunoregion polymorphism and ADR
61. Possibilities for the furture
62. Future directions
63. More to come

Topics Covered

• Type A and B Adverse Drug Reactions (ADRs)
• Pharmacokineticpharmacodynamic paradigm
• ADME framework
• Mechanisms of ADRs
• Pharmacogenetics and pharmacogenomics
• Polygenic traits
• Environmental factors
• Phenotype and endophenotype
• Candidate genes
• Association and linkage disequilibrium

Links

Series:

• Psychopharmacogenetics

Categories:

• Genetics & Epigenetics
• Neuroscience
• Pharmaceutical Sciences

Talk Citation

Publication History

• Published on October 1, 2007

Financial Disclosures

• Dr. Mario Masellis has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.